REVIEW ON TUBERCULOSIS VACCINE: DEVELOPMENT AND IMPLEMENTATION A CHALLENGE
Main Article Content
Keywords
Abstract
Tuberculosis continues to be among the leading causes of morbidity as well as mortality. It is appreciated that our aim of eliminating TB in the foreseable future will not be realized until we have a new vaccine with significant efficacy among diverse populations and all age-groups. Although impressive strides have been made in more refined development of new TB vaccines based on learnings from past experiences, the substitute or a booster vaccine for the BCG vaccine is not available yet. This article puts in perspective the recent efforts in re-positioning BCG, development of newer vaccines based on novel approaches, the current TB vaccine pipeline, and the unmet challenges faced in vaccine development, exploring newer ideas in vaccine development and what the future holds for it.
References
2. Knowledge base for the National TB Elimination Program - NTEP. Evolution of TB Programme in India. Available from: https://ntep.in/node/116/CP-evolution-tb-elimination- programme-india; accessed on November 15, 2024.
3. Modelling studies suggest that to achieve an accelerated decline, a new TB vaccine will be required in addition to a shorter treatment regimen for active TB as well as latent TB, a point-of-care diagnostic test and greater efforts at preventing transmission of infection
4. World Health Organization. End TB strategy, Global strategy and targets for tuberculosis prevention, care and control after 2015. Available from: https://cdn.who.int/media/docs/ default-source/documents/tuberculosis/end-tb-strategy- information-sheet8817f818-feaa-49ac-b26a-92c5b9dca034. pdf?sfvrsn=d6235a67_1&download=true, accessed on October 20, 2024.
5. Stop TB Partnership. AEC/BC02. Available from: https:// newtbvaccines.org/vaccine/aec-bc02/; accessed on November 14, 2024.
6. STOP TB Partnership Working Group on New TB Vaccines. Terms of TB vaccine pipeline; 2023. https://newtbvaccines.org/tb- vaccine- pipeline/TBVaccine; [ac- cessed 15 January 2024].
7. Treatment Action Group pipeline report. Tuberculosis vaccines; 2023. https://www.treatment actiongroup.org/wp- content/uploads/2023/10/ 2023_pipeline_TB_vaccines_final.pdf; [accessed 21 December 2023].
8. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille calmette-guerin induces NOD2-dependent nonspecific protection from reinfec- tion via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 2012;109:17537–42. doi:10.1073/pnas.1202870109.
9. Roth AE, Stensballe LG, Garly ML, Aaby P. Beneficial non-targeted effects of BCG–ethical implications for the coming introduction of new TB vaccines. Tu- berculosis (Edinb) 2006;86:397–403. doi:10.1016/j.tube.2006.02.001.
10. Tarancón R, Domínguez-Andrés J, Uranga S, Ferreira AV, Groh LA, Domenech M, et al. New live attenuated tuberculosis vaccine MTBVAC induces trained im- munity and confers protection against experimental lethal pneumonia. PLoS Pathog 2020;16:e1008404. doi:10.1371 /journal.ppat.1008404.
11. Roth AE, Stensballe LG, Garly ML, Aaby P. Beneficial non-targeted effects of BCG–ethical implications for the coming introduction of new TB vaccines. Tu- berculosis (Edinb) 2006;86:397–403. doi:10.1016/j.tube.2006.02.001.
12. Darrah PA, Zeppa JJ, Maiello P, Hackney JA, Wadsworth MH II, Hughes TK, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature 2020;577:95–102. doi:10.1038/s41586- 019- 1817- 8.
13. Dijkman K, Sombroek CC, Vervenne RAW, Hofman SO, Boot C, Remarque EJ, et al. Prevention of tuberculosis infection and disease by local BCG in re- peatedly exposed rhesus macaques. Nat Med 2019;25:255–62. doi:10.1038/ s41591- 018- 0319- 9.
14. Smaill F, Xing Z. Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future? Expert Rev Vaccines 2014; 1 : 927-30.
15. Sharma SK, Katoch K, Sarin R, Balambal R, Kumar Jain N, Patel N, et al. Efficacy and safety of mycobacterium indicus pranii as an adjunct therapy in category II pulmonary tuberculosis in a randomized trial. Sci Rep 2017; 7 : 3354.
16. World Health Organisation WHO product & delivery research; 2024. https://www.who.int/teams /immunization- vaccines- and- biologicals/ product-and-delivery-research/ppcs; [accessed 15 January 2024].
17. Rangaka MX, Frick M, Churchyard G, García-Basteiro AL, Hatherill M, Hanekom W, et al. Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment. Lancet Respir Med 2023;11:380–90. doi:10.1016/S2213-2600(23)00084-X.
18. World Health Organization A global framework to prepare for country introduc- tion of new TB vaccines for adolescents and adults [Draft for public consultation]; 2023. https://www.who.int/publications/m/item/a- global- framework- to- prepare- for- country- introduction- of- new- tb- vaccines- for- adults- and- adolescents; [accessed 15 January 2024].
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Nishtha Singh
Assistant Professor, Hind Institute of Medical Sciences, Barabanki
Nidhi Bhatnagar
Assistant Professor, Hind Institute of Medical Sciences, Barabanki
Sheetal Agarwal
Assistant Professor, Hind Institute of Medical Sciences, Barabanki
Kalpana Kuntal
Senior Resident, King George Medical University, Lucknow
Amit Kumar
Assistant Professor, Autonomous State Medical College, Kanpur Dehat